Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen, Inc. | 2.59% | 282.27 | 1.4% | $834.68m | |
| AMGN | Amgen, Inc. | 1.08% | 220.86 | 1.3% | $513.58m | |
| CELG | Celgene Corp. | 0.00% | 110.02 | 1.3% | $462.62m | |
| GILD | Gilead Sciences, Inc. | 1.98% | 65.07 | 1.0% | $394.92m | |
| ILMN | Illumina, Inc. | 2.53% | 305.99 | 3.5% | $310.20m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 2.34% | 209.80 | 1.9% | $306.11m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.92% | 344.87 | 2.6% | $266.59m | |
| EXAS | EXACT Sciences Corp. | 3.55% | 82.05 | 24.0% | $204.39m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 2.34% | 108.37 | 2.0% | $184.52m | |
| SGEN | Seattle Genetics, Inc. | 1.29% | 114.75 | 6.1% | $136.97m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.71% | 75.04 | 4.3% | $119.46m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.05% | 97.46 | 14.6% | $114.07m | |
| A | Agilent Technologies, Inc. | 1.95% | 78.26 | 1.6% | $103.48m | |
| NBIX | Neurocrine Biosciences, Inc. | 2.89% | 113.05 | 5.0% | $89.30m | |
| BGNE | BeiGene Ltd. | 0.94% | 198.25 | 2.1% | $85.33m |
Company Profile
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.